Co-Diagnostics, Inc. Common Stock Market Cap ($1.40 Million)
Market Cap & Net Worth: Co-Diagnostics, Inc. Common Stock (CODX)
Co-Diagnostics, Inc. Common Stock market cap. Co-Diagnostics, Inc. Common Stock (NASDAQ:CODX) has a market capitalization of $1.40 Million ($1.40 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30394 globally and #6195 in its home market, demonstrating a -30.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Co-Diagnostics, Inc. Common Stock's stock price $0.38 by its total outstanding shares 3685314 (3.69 Million). Also see cash flow conversion of Co-Diagnostics, Inc. Common Stock for how efficiently the company converts equity into cash flow.
Co-Diagnostics, Inc. Common Stock Market Cap History (2017–2026)
Co-Diagnostics, Inc. Common Stock market cap history from 2017 to 2026. Data shows change from $9.73 Million to $1.40 Million (-25.37% CAGR). Check today's stock price for Co-Diagnostics, Inc. Common Stock for real-time trading data and today's change.
Index Memberships
Co-Diagnostics, Inc. Common Stock is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #888 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2819 of 3165 |
Weight: Co-Diagnostics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Co-Diagnostics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Co-Diagnostics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Co-Diagnostics, Inc. Common Stock to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.00x
Co-Diagnostics, Inc. Common Stock's market cap is 1.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $9.73 Million | $7.66K | -$6.96 Million | 1269.80x | N/A |
| 2018 | $5.49 Million | $39.91K | -$6.27 Million | 137.58x | N/A |
| 2019 | $3.30 Million | $214.97K | -$6.20 Million | 15.35x | N/A |
| 2020 | $34.27 Million | $74.55 Million | $42.48 Million | 0.46x | 0.81x |
| 2021 | $32.91 Million | $97.89 Million | $36.66 Million | 0.34x | 0.90x |
| 2022 | $9.29 Million | $34.22 Million | -$14.24 Million | 0.27x | N/A |
| 2023 | $4.90 Million | $6.81 Million | -$35.33 Million | 0.72x | N/A |
| 2024 | $2.76 Million | $3.92 Million | -$37.64 Million | 0.71x | N/A |
| 2025 | $621.34K | $622.49K | -$46.90 Million | 1.00x | N/A |
Competitor Companies of CODX by Market Capitalization
Companies near Co-Diagnostics, Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see total assets of Co-Diagnostics, Inc. Common Stock for a full breakdown of the balance sheet.
Key companies related to Co-Diagnostics, Inc. Common Stock by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #110 globally with a market cap of $190.23 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #204 globally with a market cap of $119.12 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #226 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #110 | Abbott Laboratories | NYSE:ABT | $190.23 Billion | $109.40 |
| #204 | Stryker Corporation | NYSE:SYK | $119.12 Billion | $310.55 |
| #226 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $98.88 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Co-Diagnostics, Inc. Common Stock (2017–2026)
Market capitalization of Co-Diagnostics, Inc. Common Stock from 2017 to today. Between 2017 and today, Co-Diagnostics, Inc. Common Stock's market cap moved from $9.73 Million to $ 1.40 Million, with a yearly change of -25.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.40 Million | +125.39% |
| 2025 | $621.34K | -77.52% |
| 2024 | $2.76 Million | -43.61% |
| 2023 | $4.90 Million | -47.22% |
| 2022 | $9.29 Million | -71.78% |
| 2021 | $32.91 Million | -3.98% |
| 2020 | $34.27 Million | +938.87% |
| 2019 | $3.30 Million | -39.92% |
| 2018 | $5.49 Million | -43.56% |
| 2017 | $9.73 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Co-Diagnostics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.40 Million USD |
| MoneyControl | $1.40 Million USD |
| MarketWatch | $1.40 Million USD |
| marketcap.company | $1.40 Million USD |
| Reuters | $1.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provide… Read more